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1222Objective: Ex vivo lung perfusion has the potential to increase the number of patients treated with lung trans-
plantation. Our initial clinical experience with ex vivo lung perfusion is reviewed as well as early clinical out-
come in patients transplanted with reconditioned lungs.
Methods: Six pairs of donor lungs deemed unsuitable for transplantation underwent ex vivo lung perfusion with
Steen solution mixed with red blood cells to a hematocrit of 10% to 15%. After reconditioning, lung function
was evaluated and acceptable lungs were transplanted. Technical experience with ex vivo lung perfusion as well
as clinical outcome for patients transplanted with ex vivo lung perfusion-treated lungs were evaluated.
Results:Donor lungs initially rejected either as a result of an inferior partial pressure of arterial oxygen/ fraction
of inspired oxygen (n ¼ 5; mean, 20.5 kPa; range, 9.1-29.9 kPa) or infiltrate on chest radiograph (n ¼ 1) im-
proved their oxygenation capacity to a mean partial pressure of arterial oxygen/fraction of inspired oxygen of
57 10 kPa during the ex vivo lung perfusion (mean improvement, 33.6 kPa; range, 21-51 kPa; P<.01). During
evaluation, hemodynamic (flow, vascular resistance, pressure) and respiratory (peak airway pressure, compli-
ance) parameters were stable. Two single lungs were not used for lung transplantation because of subpleural
hematoma or edema. Six recipients from the regular waiting list underwent single (n ¼ 2) or double (n ¼ 4)
lung transplantation. One patient had primary graft dysfunction grade 2 at 72 hours. Median time to extubation
was 7 hours. All patients survived 30 days and were discharged in good condition from the hospital.
Conclusions: The use of ex vivo lung perfusion seems safe and indicates that some lungs otherwise refused for
lung transplantation can be recovered and transplanted with acceptable short-term results. (J Thorac Cardiovasc
Surg 2012;144:1222-8)Lung transplantation (LTx) is the treatment of choice for
end-stage lung disease, but the shortage of donor lungs re-
mains the limiting factor. Recent national data from the
United States reports use of 22% of lungs from multiorgan
donors; corresponding U.K. data indicate 17%.1,2 After
improvements in donor management and implementation
of extended donor criteria, lungs from as many as 30% to
40% of multiorgan donors in Sweden have been
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The Journal of Thoracic and Cardiovascular SurReconditioning and evaluation of lungs initially rejected
for transplantation with ex vivo lung perfusion (EVLP) has
been used to differentiate reversible from irreversible pa-
thology.3-5 In 2007, Steen and colleagues6 reported the first
transplantation of an ex vivo reconditioned lung. Thereafter,
transplantations of initially rejected but EVLP recondi-
tioned lungs from brain dead donors have been reported
in 32 patients from 4 centers.4,5,7,8 We present our early
clinical experience with EVLP management of initially
rejected donor lungs with subsequent LTx.MATERIALS AND METHODS
Patients
The Ethics committee of the University of Gothenburg approved this
study. All recipients on the LTx waiting list were eligible for transplanta-
tion with lungs reconditioned with EVLP. Recipients were matched for
compatible blood group, size, and urgency, and were brought to the trans-
plantation center during the organ retrieval procedure. Recipient character-
istics are presented in Table 1.
Donor Selection and Characteristics
Between January 2011 and October 2011, lungs from 107 brain dead
donors were offered to our center; 27 were accepted for transplantation
and 80 were rejected because of no matching recipient (26%); advanced
smoking history (18%); high donor age (14%); inferior blood gases de-
spite efforts such as recruitment maneuvers, bronchial suction, and diureticgery c November 2012
Abbreviations and Acronyms
CO2 ¼ carbon dioxide
EVLP ¼ ex vivo lung perfusion
FiO2 ¼ fraction of inspired oxygen
LTx ¼ lung transplantation
PA ¼ pulmonary artery
PaO2 ¼ partial pressure of arterial oxygen
PEEP ¼ positive end-expiratory pressure
P/F ¼ ratio of the partial pressure of arterial
oxygen to the fraction of inspired oxygen
PO2 ¼ partial pressure of oxygen
PVR ¼ pulmonary vascular resistance
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Xtreatment (8%); aspiration of gastric content (8%); and other signs of in-
ferior lung function, trauma, macroscopic abnormalities, or unclear rea-
sons (19%). Six pairs of the rejected donor lungs were subjected to
EVLP. Criteria for EVLP evaluation were (1) best ratio of the partial pres-
sure of arterial oxygen to the fraction of inspired oxygen (P/F) in the inten-
sive care unit <40 kPa; and/or (2) radiologic signs of extensive lung
edema; and/or (3) radiologic signs of infiltrates suggestive of pneumonia,
lung infarction, or aspiration.
The lungs were harvested in a standard fashion with antegrade Perfadex
(Vitrolife AB, Gothenburg, Sweden) flush, cold storage in Perfadex and
were kept on ice during transport. If the heart was harvested, an additional
piece of the ascending aorta was brought for elongation of the pulmonary
artery (PA) to facilitate connection of the lung to the EVLP artery cannula.
For detailed donor characteristics see Table 2.
Ex Vivo Lung Perfusion
EVLP was performed with the CE-marked Vivoline LS1 (Vivoline
Medical AB, Lund, Sweden) (Figures 1 and 2). The system was primed
with 2.0 L of Steen Solution (Vitrolife AB) mixed to a hematocrit level
of 10% to 15% with bank blood, compatible and cross-checked to the se-
lected recipient. Meropenem 100 mg (AstraZeneca AB, Sodertalje, Swe-
den) and 10000E Heparin (LEO Pharmaceutical, Copenhagen, Denmark)
were added to the perfusate. Before the lungs were connected to the
EVLP unit, the pH in the solution was corrected to between 7.35 and
7.45 with isotonic trometamol (Addex-THAM, Fresenius Kabi AB,
Uppsala, Sweden).
To perform a safe cannulation of the PA, a 3- to 4-cm graft of the ascend-
ing aorta from the donor was used to elongate the PA in 3 cases. The trachea
was connected to the mechanical ventilator via a silicon tube size matched
for the tracheal diameter. The remnant of the left atriumwas opened widely
to prevent pulmonary vein outflow obstruction and to keep left atrial pres-
sure near 0 mmHg. A temperature probe was sutured inside the left atrium.
All perfusion was performed in an antegrade fashion. Figure 1 illustrates
the setup of the lung in the EVLP system.
The different EVLP phases (Figure 3) were as follows:
Reconditioning phase. Initially, the lungs were perfused at a flow
rate of 0.5 L/min. The shunt from the inflow cannula was closed when
the perfusate was de-aired. The lungs were warmed to a target of 36C,
and the temperature difference between lung blood inflow and outflow
was not allowed to exceed 8C. The flow rate was increased gradually to
a target level of 70 mL/min per kilogram donor weight, during which the
PA pressure was measured continuously and limited to 15 mmHg. If initial
perfusion was uneventful, the PA pressure limit was increased to 20 mm
Hg. When the temperature reached 32C, mechanical volume-controlled
ventilation was started at an initial minute-volume of 1.5 times the PAThe Journal of Thoracic and Carflow, a positive end-expiratory pressure (PEEP) level of 5 cm H2O, a rate
of 12 breaths/min, and an FiO2 of 0.5. If uneventful, ventilation was in-
creased gradually to a maximum of 100 mL/min per kilogram donor
weight. At 36C, an incremental PEEP trial was performed to recruit ate-
lectatic lobes/segments. Blood samples for gas analysis were drawn from
the left atrium and, if deemed acceptable, EVLP was shifted to the evalu-
ation phase. If blood gases were suboptimal, further treatment was per-
formed in the reconditioning phase.
Evaluation phase. The oxygenator was now used to deoxygenate the
perfusate and to add carbon dioxide (CO2). Tenminutes after the start of the
evaluation phase, samples for blood gas analysis were drawn from the left
atrium and from the circuit after the oxygenator in the EVLP system (the
latter to make sure that the perfusate was deoxygenated adequately). FiO2
was then decreased to 0.21 and, after another 10-minute period, new blood
samples were drawn. FiO2 was finally set to 1.0 followed by a third set of
blood gas analyses. A collapse test was performed at FiO2 1.0 by discon-
necting the tracheal tube at the end of inspiration. Recoil of the lungs was
evaluated subjectively. Pulmonarymechanics as well as end-tidal CO2 con-
centrationsweremonitored continuously (Datex-OhmedaAnesthesiaMon-
itor; GE Health Care, Chalfont St. Giles, UK). Physiologic dead space was
calculated as (PaCO2End-tidal CO2)/PaCO2. Static lung compliance was
defined as Tidal volume/(Inspiratory plateau pressurePEEP). Left atrial
pressure was assumed to be 0 mm Hg, and pulmonary vascular resistance
(PVR) was consequently defined as Mean PA pressure/PA flow 3 80.
Acceptance of EVLP-evaluated lungs for transplanta-
tion. The decision to transplant the lungs was based on (1) a lung oxy-
genation capacity with a P/F ratio of >40 kPa during the evaluation
phase, (2) stable hemodynamic and respiratory variables (PVR, peak air-
way pressures, and lung compliance) during EVLP, (3) absence of macro-
scopic signs of pneumonic infiltrates or lung infarctions, and (4) a normal
collapse test.
After the evaluation test, the lungs were cooled in the EVLP system (core
cooling) to12C.Theventilatorwasdisconnected at32Cand the tracheawas
clamped when 50% of the tidal volume was exhaled. In the first 2 pair of
lungs, the PAwas clamped after an antegrade flush of 1 L Perfadex with ad-
ditivesat 12C, and thereafter stored inPerfadex on ice.The subsequentdonor
lungs (n¼ 4) had surface cooling instituted with the EVLP perfusate contin-
uously flowing over the compress-imbedded lungs. Temperature of the donor
lungs during surface coolingwere kept at 8C. In case of double LTx, the sec-
ond lung was kept cold by continuous surface cooling as the first lung was
transplanted.
Lung Transplantation
When possible, surgery was performed as bilateral sequential thoracot-
omies without extracorporeal circulation. Postoperatively, the patients who
underwent LTx received treatment according to our standard protocol for
LTx. Lung spirometry was performed at the time of discharge from the
hospital.
Statistical Analysis
Data were collected prospectively. Continuous data are presented as
mean and range. Categorical data are presented as frequency and percent-
age. Early mortality was defined as hospital mortality, which is all-cause
death within any time interval after the LTx. Differences between values
before and after treatment were calculated with the Wilcoxon signed-
rank test. A P value of<.05 was considered as statistically significant.RESULTS
Six pair of lungs were evaluated with EVLP. The evalu-
ated lungs were initially rejected for LTx as a result of infe-
rior blood gases in the intensive care unit (n ¼ 5) or
advanced bilateral infiltrates on chest radiograph (n ¼ 1).diovascular Surgery c Volume 144, Number 5 1223
TABLE 1. Recipient characteristics
Variable
Recipient
1 2 3 4 5 6 Mean
Age, y 56 55 29 17 51 69 46
Height, cm 160 170 171 151 178 168 166
Weight, kg 55 61 52 41 84 78 62
Blood group A A A A B B
Diagnosis COPD COPD CF KS COPD Fibrosis
FVC, L/% of
predicted
1.7/62 1.9/59 2.0/43 2.0/58 2.7/59 1.4/51 1.95
FEV 1.0, L/%
of predicted
0.5/22 0.5/26 1.1/31 1.0/32 0.8/22 1.2/52 0.85
COPD, Chronic obstructive pulmonary disease; CF, cystic fibrosis; KS, Kartagener
syndrome; FVC, forced vital capacity;FEV 1.0, forced expiratory volume in 1 second.
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optimization of lung function. After EVLP, 2 single lungs
were still deemed unsuitable as a result of consolidation
or edema and were not used for LTx. Donor characteristics
are described in Table 2.EVLP Outcome
In EVLP no. 1, the lungs were rejected at a P/F ratio of
16.7 kPa. Chest radiography showed basal infiltrates. After
134 min of EVLP, the P/F ratio improved to 67.4 kPa. A PA
flow of 77% of the estimated was reached at a PA pressure
of 20mmHg. PVRwas stable around 580 dynes  sec  cm5.
Double LTx was performed and the recipient had an
uneventful recovery.
In EVLP no. 2, the lungs were rejected at a P/F ratio of
17.0 kPa. Chest radiography showed edema. After 220 min
of EVLP, the P/F ratio improved to 40.6 kPa. A PA flow of
55% of the estimated was reached at a PA pressure of 20
mm Hg. PVR was reasonably stable around 650 dynes 
sec  cm5. The lung weight decreased from 2550 g to
1950 g. The intended double LTx was converted to single
LTx because of complicated recipient lung adhesions. It
was also assumed that transplantation of the second lungTABLE 2. Donor characteristics
Variable 1 2 3
Age, y 22 52 42
Height, cm 170 168 172
Weight, kg 80 66 62
Blood group A A A
Cause of death SAH SAH SAH
P/F ratio (in donor
when accepted for EVLP)
16.7 17 29.8
Radiographic findings Bilateral basal infiltrate Edema Infiltrate, edem
Transport, min; cold flush to
start EVLP
143 217 216
SAH, Subarachnoid hemorrhage; SDH, subdural hemorrhage; IBI, ischemic brain injury; P/F
lung perfusion.
1224 The Journal of Thoracic and Cardiovascular Surwould result in the need for extra corporeal circulation dur-
ing or after the procedure because of severely impaired
blood gases after transplantation of the first lung. The de-
cision to not transplant the second lung was supported by
the fact that the patient was planned for either single or
double LTx. Indeed, the transplanted lung showed immedi-
ate signs of dysfunction in terms of extensive lung edema.
The recipient had primary graft dysfunction grade 2 at 36
hours and was dependent on mechanical ventilation for 24
days.
In EVLP no. 3, the lungs were rejected at a P/F ratio of
29.8 kPa. Chest radiography showed localized infiltrate
and edema. After 116 min of EVLP, the P/F ratio improved
to 56.8 kPa. PA flow was not restricted by the PA pressure
limit. PVRwas stable around 300 dynes  sec  cm5. Double
LTx was performed and the recipient had an uneventful
recovery.
In EVLP no. 4, the lungs were rejected at a P/F ratio of
41.8 kPa. Chest radiography showed extensive bilateral in-
filtrates. After 93 min of EVLP, the P/F ratio improved to
70.2 kPa. PAflowwas not restricted by the PApressure limit.
PVR was stable around 370 dynes  sec  cm5. Double LTx
was performed and the recipient had an uneventful recovery.
In EVLP no. 5, the lungs were rejected at a P/F ratio of
29.9 kPa. Chest radiography showed bilateral basal infil-
trates. After 112 min of EVLP, the P/F ratio improved to
49.9 kPa. PAflowwas not restricted by the PApressure limit.
PVR was stable around 245 dynes  sec  cm5. Double LTx
was performed and the recipient had an uneventful recovery.
In EVLP no. 6, the lungs were rejected at a P/F ratio of
9.1 kPa. Chest radiography showed extensive infiltrate on
the right side. After 295 min of EVLP, the P/F ratio im-
proved to 59.6 kPa in the left lung and remained at 13.6
in the right lung, which was severely consolidated. PA
flow was not restricted by the PA pressure limit. PVR was
stable around 320 dynes  sec  cm5. The lung weight de-
creased from 1650 g to 1250 g. Single LTx was performed
and the recipient had an uneventful recovery.Donor no.
4 5 6 Mean
52 59 19 41
145 180 175 168
61 102 55 71
A B B
SAH SDH IBI
41.8 29.9 9.1 24.1
a Bilateral infiltrate Bilateral basal infiltrate Extensive infiltrate
191 221 336 220
, ratio of partial pressure of arterial oxygen/fraction of inspired oxygen; EVLP, ex vivo
gery c November 2012
FIGURE 1. Schematic drawing of the ex vivo lung perfusion unit. The
blood enters the open reservoir via the remnant of the left atrium. Samples
for blood gas analyses are drawn from the left atrium (LA) and from a port
after the oxygenator where drugs can also be administered. PA, Pulmonary
artery; HCU, Heater-cooler unit.
Wallinder et al Cardiothoracic TransplantationDetailed data from EVLP are presented in Tables 3
through 5. Mean duration of EVLP was 231 min. The
mean reconditioning time was 104 min before initiation
of the evaluation phase. Two pairs of lungs (nos. 2 and 6)
were heavy with edema and reconditioned for 162 and
242 minutes, respectively. These 2 pairs of lungs had the
lowest P/F ratios and the lowest lung compliance (both 53
mL/cm H2O).FIGURE 2. Picture of a setup of the lung in the Vivoline ex vivo lung per-
fusion circuit. Cannula to pulmonary artery in top. Cannula to trachea in
bottom. Shunt closed with plastic clamp in upper right corner. White tem-
perature probe crossing the lung.
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33.6 kPa (range, 21.0-50.7 kPa) compared with the donor
P/F ratio (range, 9.1-41.8 KPa).
Mean peak airway pressure was 15.3 cm H2O at FiO2 1.0
and did not exceed 18 cm H2O in any pair of lungs. Mean
static lung compliance at the end of EVLP was 59 mL/cm
H2O (range, 53-65 mL/cm H2O). Mean dead space fraction
was 35% (range, 17-45%). In 2 pairs of lungs (nos. 1 and
2), PA flow was limited (77% and 50% of target, respec-
tively) by the preset upper PA pressure limit of 20 mm
Hg. These 2 pairs of lungs had a high dead space fraction
(43% and 44%). In the remaining 4 pairs of lungs (nos.
3-6), the target flow of 70 mL/min per kilogram donor
weight was reached. These 4 pairs of lungs had a consider-
able lower mean dead space fraction of 30%. PVRwere sta-
ble during the reconditioning and evaluation phases, even
beyond 4 hours of perfusion (Figure 4). Hematocrit in-
creased during EVLP from a mean of 11.8 to 12.8
(P ¼ .03), and blood glucose decreased from a mean of
12 mmol/L to 9.3 mmol/L (P ¼ .03).
Early Clinical Results
All LTx were performed without the use of extracorpo-
real circulation. There was no 30-day or hospital mortality
and all patients were discharged from hospital after
a mean stay of 31 days (range, 25-44 days). Early lung func-
tion test prior to discharge showed that the patients, on av-
erage, had 70% of anticipated forced expiratory volume at 1
second (FEV 1.0). Data are presented in Table 6.
DISCUSSION
Our results indicate that lungs initially rejected for dona-
tion because of impaired function can be recovered during
EVLP and eventually transplanted without compromising
early clinical results. Six patients underwent successful
LTx with initially rejected donor lungs. In 5 donors, blood
gases were impaired to the extent that the lungs were
deemed unusable. In 1 donor, bilateral infiltrates disquali-
fied the lungs for transplantation, although the P/F ratio
was>40 kPa. All donors had varying extent of pathologic
findings on chest radiography. In our program, none of the
lungs would normally have been used for transplantation
prior to the introduction of EVLP.
Two different EVLP protocols for human lungs have
been applied for clinical use. The Toronto group has devel-
oped an EVLP technique with low PA flow (40% of esti-
mated cardiac output), low PA pressure (10-15 mm Hg),
and acellular Steen solution.5 We have adopted the EVLP
protocol initially described by Steen and colleagues6 that
allows higher PA flow and pressures. Perfusion is per-
formed with Steen solution mixed with banked blood to
a hematocrit of 10%-15%. In an animal study of lungs
from nonheart-beating donors with warm ischemic times
of more than 1 hour, it was shown that PVR increaseddiovascular Surgery c Volume 144, Number 5 1225
FIGURE 3. The practical, circulatory, and ventilatory settings of the different phases during ex vivo lung perfusion. FiO2, Fraction of inspired oxygen.
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cells in the perfusate.9 Based on that study, it has been ques-
tioned whether perfusion with red blood cells can be per-
formed safely for longer than 2 hours,10 which is
sometimes needed for proper ex vivo reconditioning. How-
ever, in our series, lungs underwent EVLP for up to 5 hours
with no marked increase of PVR over time, with the excep-
tion of temporary elevations seen in conjunction with lung
recruitment maneuvers. During the end of EVLP, when the
cooling phase is instituted, and the lung becomes cold and
less compliant, PVR tends to increase (Figure 3). Cypel and
associates11 suggested that low flow is essential for suc-
cessful EVLP. This might hold true when extended perfu-
sions are anticipated, for example, in experimental organ
treatment purposes. In our opinion, however, the evaluation
of the lung function ex vivo should always be performed
using as normal physiologic conditions as possible with re-
spect to PA flow and pressure, blood corpuscle-containing
perfusate, as well as ventilatory settings. Functional testing
at low flow and low PA pressure during EVLP is notTABLE 3. Ex vivo lung perfusion duration data
Variables 1 2
From start to 32C, min 30 4
From start to 36C, min 44 7
Reconditioning 61 16
Evaluation 61 3
Core cooling 59 8
Total EVLP, min 193 30
Cooling method, after EVLP Ice Ic
Duration, post-EVLP cooling, lung 1, min 299 28
Duration, post-EVLP cooling, lung 2, min 438 N/
Total time lung 1, harvest to recipient perfusion, min 643 80
Total time lung 2, harvest to recipient perfusion, min 782 N/
EVLP, Ex vivo lung perfusion; SC, surface cooling;N/A, not applicable. *A first evaluation
in the right lung, the phase was shifted back to reconditioning. After a total EVLP time o
1226 The Journal of Thoracic and Cardiovascular Surcongruent with the environment in which the lung should
later function.
The duration of EVLP was, in the current study, in the
range of 157 to 393 minutes. A range of 53 to 98 minutes
of this time was used for cooling. The seemingly large
time differences are a consequence of the time needed
to reach acceptable lung performance. In concurrence,
with Aigner and coworkers,8 we believe that no further
time needs to be spent on EVLP if blood gas values and
circulatory and ventilatory data are satisfactory. On the
other hand, if the initial physiologic variables are subopti-
mal, the reconditioning phase should be prolonged to pro-
vide time for the oncotic effect of the hyperoncotic
perfusate to reduce lung water. All lungs reconditioned
during EVLP increased their oxygenation capacity com-
pared with donor blood gas recordings at time of accep-
tance. In this series, we believe that the most important
reason for improvement of lung function is recruitment
of atelectasis together with extensive clearance of bron-
chial secretion.EVLP duration data
3 4 5 6 Mean
0 27 27 23 23 28
9 50 37 43 60 52
2 58 55 50 242* 104
2 58 42 62 53 51
5 53 60 62 98 70
5 169 157 174 393 231
e SC SC SC SC —
5 328 303 237 260 285
A 537 480 455 N/A 478
7 713 701 632 1049 758
A 923 878 850 N/A 858
was done after 68 minutes. As a result of suboptimal partial pressure of arterial oxygen
f 242 minutes, another evaluation was performed for which data are presented.
gery c November 2012
TABLE 4. Ex vivo lung perfusion hemodynamic and respiratory data
Variables
EVLP no.
1 2 3 4 5 6 Mean
P/F ratio, 0.5 29.8 15.8 29.3 37.7 22 25.7L, 7.7R 26.7
P/F ratio, 0.21 11.4 MD 14.9 18 9.7 9.9L, 5.9R 12.8
P/F ratio, 1.0 67.4 40.6 56.8 70.2 49.9 59.6L, 13.6R 57.4
Ventilation, L/min, at FiO2 1.0 4.3 4.7 6 6 6 3.8 5.1
PawP, mm Hg, at FiO2 1.0 12 15 17 16 15 13 15
Compliance at FiO2 1.0 56 53 65 64 63 53 59
DSF,%, at FiO2 1.0 44 43 45 17 32 28 35
PaO2 improvement from donor to EVLP FiO2 1.0 (best lung) 50.7 23.6 27.1 28.4 21.0 50.5 33.6
PA flow, L/min, at FiO2 1.0 4.3 2.4 4 4.2 6 3.9 4.1
PA maximum flow,% of predicted, at FiO2 1.0 77 55 100 100 100 100
PA pressure, mm Hg, at FiO2 1.0 19 20 15 19 18 16 18
PVR, dynes  s  cm5, at FiO2 1.0 576 682 308 371 240 330 418
EVLP, Ex vivo lung perfusion; P/F, ratio of partial pressure of arterial oxygen/fraction of inspired oxygen; L, left lung; R, right lung;MD, missing data; PawP, peak airway pres-
sure; DSF, dead space fraction; PVR, pulmonary vascular resistance.
Wallinder et al Cardiothoracic TransplantationGlucose levels decreased and lactate levels increased dur-
ing EVLP, as reported by others.12,13 We do not believe
these are signs of impaired lung function. On the contrary,
we find them congruent with normal lung metabolism as
described previously.14 The pairs of lungs (nos. 2 and 6)
with the poorest function were subjected to a longer
EVLP time, and consequently developed lower glucose
and higher lactate levels than the others.
In theory, one of the main objectives of EVLP is to mo-
bilize extensive interstitial and/or alveolar fluid to the
hyperoncotic perfusate. However, because 3 of 6 lungs
gained weight during EVLP, we are not convinced that
this is the main reason for improvement of the lung func-
tion. On the other hand, in lungs heavy with fluid prior to
EVLP, as in 2 pairs of our lungs (nos. 2 and 6; weight,
>1500 g), fluid shift from the lung to the perfusate seems
a likely explanation for some of the improved lung function.
One of these pairs of lungs (no. 2) was by far the heaviest
and had the worst oxygenation capacity of all donor lungs.
Although improvement was seen during EVLP, theTABLE 5. Ex vivo lung perfusion laboratory data
Variable
EVLP no.
1 2 3 4 5 6 Mean
Hct start,% 12.3 10.9 11.1 10.7 12.4 13.3 11.8
Hct final,% 12.9 11.7 11.6 11.4 13.2 16 12.8
DHct,% 0.6 0.8 0.5 0.7 0.8 2.7 1.0
B-glucose start,
mmol/L
11.3 10.1 12.6 12.5 13.6 11.8 12.0
B-glucose final,
mmol/L
10.0 4.3 11.7 9.8 10.7 <0.1 7.8
Weight start, g MD 2550 600 500 750 1650 1210
Weight final, g MD 1950 1050 1000 1000 1250 1250
DWeight, g MD 650 450 500 250 400 10
EVLP, Ex vivo lung perfusion; Hct, hematocrit; MD, missing data; DWeight, change
in lung weight before and after EVLP core cooling.
The Journal of Thoracic and Caroxygenation capacity just reached the preset requirements
for transplantation. The recipient operation was compli-
cated and, therefore, lungs with very extensive edema and
oxygenation capacity just reaching 40 kPa after EVLP
should be considered carefully before transplantation. A
lesson learned from this suboptimal outcome, with postop-
erative morbidity as well as a less-than-ideal postoperative
lung function, is that either transplantation should not have
been performed in this patient or both donor lungs should
have been implanted with postoperative extracorporeal
membrane oxygenation. All other patients had an accept-
able outcome with no mortality, low morbidity, and good
lung function at discharge from hospital.
The yield of transplantation after EVLPwas 100% in this
series, which is higher than that reported by others.4,5,8 Two
single lungs, however, were deemed unsuitable for
transplantation in our series. We continue to evaluate
selected, rejected donor lungs with EVLP.FIGURE 4. PVR over time in 6 lungs during ex vivo lung perfusion. PVR,
Pulmonary vascular resistance.
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TABLE 6. Patient outcome after ex vivo lung perfusion and lung transplantation
Variable
Recipient no.
1 2 3 4 5 6
Procedure DL SL DL DL DL SL
ECC, Y/N N N N N N N
Time to extubation, h 3 574 6 7 5 7
ICU stay, h 40 625 73 54 152 40
PGD grade at 72 hours* 0 2 0 1 1 0
Hospital stay, d 27 44 39 27 25 25
Spirometry at discharge
FEV 1.0,% expected 1.7 L, 75% 1.1 L, 40% 2.2 L, 64% 2.1 L, 76% 3.2 L, 88% 1.7 L, 74%
FVC,% expected 2.2 L, 82% 1.8 L, 56% 3.0 L, 76% 2.2 L, 69% 3.8 L, 83% 1.8 L, 66%
DL, Double lung; SL, single lung; ECC, extracorporeal circulation; Y, yes; N, no; ICU, intensive care unit; PGD, primary graft dysfunction; FEV, force expiratory volume;
FVC, force vital capacity. *PGDwas defined as grade 0, PaO2/FiO2 40 kPawith a clear chest radiograph; grade 1, PaO2 40 kPa with infiltration on chest radiographs; grade 2,
PaO2/FiO2  27 but<40 kPa; and grade 3, PaO2/FiO2<27 kPa.
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We believe that this EVLP concept is safe, and that proof-
of-concept has been shown by others. In our experience, the
Vivoline system has been reliable; however, this case series
is small and has no control group. Moreover, the included
lungs are heterogeneous and therefore conclusions have to
be drawn very cautiously.
CONCLUSIONS
In conclusion, the use of EVLP seems safe and indicates
that lungs otherwise refused for LTx can be recovered and
used subsequently for transplantation with acceptable re-
sults. However, the system comes with a considerable
cost. Larger series of patients as well as long-term data
are required before EVLP can be determined as an impor-
tant adjunct to LTx.
We thank all the participants of the lung transplant team at the
Sahlgrenska University Hospital for dedicated clinical work.References
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